PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery
Condition(s):Non-small Cell Lung CancerLast Updated:June 2, 2021Completed
Hide Studies Not Open or Pending
Condition(s):Non-small Cell Lung CancerLast Updated:June 2, 2021Completed
Condition(s):Overal Survival, Non-small Cell Lung CancerLast Updated:May 17, 2017Completed
Condition(s):Non-small Cell Lung CancerLast Updated:January 29, 2013Unknown status
Condition(s):Non-Small Cell Lung CancerLast Updated:October 31, 2023Active, not recruiting
Condition(s):Non-small Cell Lung Cancer; EGFR Gene MutationLast Updated:April 24, 2020Unknown status
Condition(s):Hepatocellular Carcinoma; Molecular Targeted TherapyLast Updated:August 1, 2023Completed
Condition(s):Lung Adenocarcinoma; EGFR MutationLast Updated:April 3, 2018Unknown status
Condition(s):Lung CancerLast Updated:December 22, 2017Not yet recruiting
Condition(s):Locally Advanced or Metastatic NSCLCLast Updated:May 12, 2022Recruiting
Condition(s):Advanced NSCLC With EGFR MutationLast Updated:July 10, 2020Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.